Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells

Po-Wen Hsiao a, Chia-Ching Chang b, Huei-Fang Liu a, Chuan-Mei Tsai b, Ted H. Chiu a, Jui-I Chao a,⁎

a Institute of Pharmacology and Toxicology, College of Life Sciences, Tzu Chi University, 701, Section 3, Chung-Yang Road, Hualien 970, Taiwan
b Department of Biological Science and Technology, National Chiao Tung University, 75 Bo-Ai Street, Hsin-Chu 300, Taiwan

Received 24 January 2007; revised 17 April 2007; accepted 17 April 2007
Available online 27 April 2007

Abstract
Cancer cells express survivin that facilitates tumorigenesis. Celecoxib has been shown to reduce human colorectal cancers. However, the role and regulation of survivin by celecoxib in colorectal carcinoma cells remain unclear. Treatment with 40–80 μM celecoxib for 24 h induced cytotoxicity and proliferation inhibition via a concentration-dependent manner in RKO colorectal carcinoma cells. Celecoxib blocked the survivin protein expression and increased the phosphorylation of H2AX at serine-193 (γ-H2AX). The survivin gene knockdown by transfection with a survivin siRNA revealed that the loss of survivin correlated with the expression of γ-H2AX. Meanwhile, celecoxib increased caspase-3 activation and apoptosis. Celecoxib activated the phosphorylation of p38 mitogen-activated protein (MAP) kinase. The phosphorylated proteins of p38 MAP kinase and γ-H2AX were observed in the apoptotic cells. SB203580, a specific p38 MAP kinase inhibitor, protected the survivin protein expression and decreased the levels of γ-H2AX and apoptosis in the celecoxib-exposed cells. The blockade of survivin expression increased the celecoxib-induced cytotoxicity; conversely, overexpression of survivin by transfection with a survivin-expressing vector raised the cancer cell proliferation and resisted the celecoxib-induced cell death. Our results provide for the first time that p38 MAP kinase participates in the down-regulation of survivin and subsequently induces the activation of γ-H2AX for mediating apoptosis following treatment with celecoxib in human colorectal cancer cells.

Keywords: Apoptosis; Celecoxib; Survivin; p38 MAP kinase; γ-H2AX; RKO cells

Introduction
Survivin is expressed in various human cancer cells and is undetectable in most normal adult cells (Ambrosini et al., 1997; Li et al., 1998; Chao et al., 2004). Survivin inhibits apoptosis and promotes mitosis (Li et al., 1998; O’Connor et al., 2000; Kuo et al., 2004). It has been shown that the anti-apoptotic effect of survivin is due to inhibition of the activity of caspases in cancer cells (Kawamura et al., 2003; Beltrami et al., 2004). Moreover, survivin may serve as a radio- and chemo-resistance factor (Rodel et al., 2003; Wall et al., 2003), and has been correlated with decreased survival, unfavorable prognosis, and accelerated rates of recurrences in cancer therapy (Altieri, 2001).

Colorectal cancer is the most common cancer and is the leading cause of cancer-related mortality around the world (Jemal et al., 2005). Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzymes and may be employed to reduce colorectal cancer growth (Steinbach et al., 2000; Keller and Giardiello, 2003; Sinicrope and Gill, 2004). Celecoxib exhibits high selectivity for the COX-2 enzyme and exerts anticarcinogenic and chemopreventive activities (Steinbach et al., 2000; Keller and Giardiello, 2003; Kismet et al., 2004). Moreover, celecoxib has been approved by the FDA of USA for adjuvant treatment in patients with familial adenomatous polyposis. Recently, celecoxib has been shown to inhibit the survivin protein expression in human cancer cells (Lin et al., 2005; Pyrko et al., 2006). However, the regulation of survivin by celecoxib is still unclear.

Anticancer agents exert their activities through the induction of apoptosis or the inhibition of proliferation in cancer cells (Tamura et al., 2000; Brantley-Finley et al., 2003). It has been proved that p38 MAP kinase is an important signal molecule to regulate apoptosis in response to various stimuli (Schwenger et al., 1997; Takekawa et al., 2000; Kim et al., 2002). Anticancer drugs can
induce the activation of p38 MAP kinase leading to the induction of apoptosis in cancer cells (Li and Bertino, 2002). Besides, p38 MAP kinase mediating apoptosis is associated with the activation of caspases (Kim et al., 2002; Li and Bertino, 2002). Nevertheless, the control of survivin expression by p38 MAP kinase in the celecoxib-induced apoptosis has not been studied.

H2AX is a variant of H2A of histones to maintain genomic stability (Paull et al., 2000; Redon et al., 2002). The phosphorylation of H2AX at serine-193, named γ-H2AX, can be induced by DNA damage agents (Paull et al., 2000; Redon et al., 2002). Moreover, the presentation of γ-H2AX phosphorylation has been shown related to caspase-controlled DNA fragmentation in the process of apoptosis (Rogakou et al., 2000).

In this study, a small interfering RNA (siRNA) and a survivin-expressed vector were employed to illustrate the role of survivin in the celecoxib-induced apoptosis. Intriguingly, the blockade of survivin increased the protein level of γ-H2AX. Furthermore, p38 MAP kinase participated in the down-regulation of survivin with subsequent induction of γ-H2AX and apoptosis after treatment with celecoxib.

**Experimental procedures**

**Materials.** Celecoxib was purchased from Toronto Research Chemical Inc. (North York, Canada) and dissolved in 80% ethanol. The concentration of ethanol was <0.4% in the control and drug-containing media. Hoechst 33258, propidium iodide (PI), 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and the Cy3-labeled mouse anti-γ-tubulin (c-4855) were purchased from Sigma Chemical Co. (St. Louis, MO). BODIPY FL phallacidin (B-607) was purchased from Invitrogen (Carlsbad, CA). Anti-ATF-2 (F2BR-1), anti-ERK-2 (C-14), anti-γ-H2AX, anti-FL (C-20), anti-survivin (FL-142), and the FITC (fluorescein isothiocyanate)-labeled goat anti-mouse IgG (sc-1010) and donkey anti-goat IgG (sc-2024) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-caspase-3 (3004-100) was purchased from BioVision Research Products (Mountain View, CA). The Cy5-labeled goat anti-rabbit IgG was purchased from Amersham Pharmacia Biotech (Little Chalfont Buckinghamshire, UK). Anti-phospho-ATF-2 (Thr-71) (9221), anti-phospho-p38 (9211), SignalSilence® survivin siRNA (#6351), and SignalSilence® control siRNA (#6201) were purchased from Cell Signaling Technology, Inc. (Beverly, MA). SB203580 was purchased from Calbiochem (San Diego, CA). Anti-phospho-Histone H2A.X (Ser139) (05-636) was purchased from Upstate (Lake Placid, NY).

**Cell culture.** RKO was a colorectal carcinoma cell line that expressed the wild-type p53 proteins. These cells were maintained in DMEM medium (Invitrogen). The complete medium was supplemented with 10% fetal bovine serum (FBS). The cells were cultured at 37 °C and 5% CO₂ in a humidified incubator (310/Thermo, Forma Scientific, Inc., Marietta, OH).

**Cytotoxicity assay.** The cells were plated in 96-well plates at a density of 1 × 10⁴ cells/well for 16–20 h. Then the cells were treated with 0–100 μM celecoxib for 24 h. At the end of treatment, the cells were washed with phosphate-buffered saline (PBS), and were re-cultured in complete medium for 2 days. Thereafter, the medium was replaced and the cells were incubated with 0.5 mg/ml RNase for 30 min. To avoid cell aggregation, the cell solutions were filtrated through nylon membrane (Becton-Dickinson, San Jose, CA). Subsequently, the samples were analyzed by flow cytometer. A minimum of ten thousand cells was analyzed for DNA content, and the percentage of cell cycle phases was quantified by a ModFit LT software (Ver. 2.0, Becton-Dickinson).

**Apoptosis analysis.** The sub-G₁ fractions were determined by flow cytometer same as above for cell cycle analysis. The percentage of sub-G₁ fractions was quantified by using CellQuest software (Becton-Dickinson). To further confirm the level of apoptotic cells, the cells were cultured on coverslip in a 60-mm Petri dish for 16–20 h before treatment. At the end of treatment, the cells were carefully and gently washed with isotonie PBS (pH 7.4), and fixed with 4% paraformaldehyde solution in PBS for 1 h at 37 °C. The nuclei were stained with 2.5 μg/ml Hoechst 33258 for 30 min. The cell morphology of apoptosis was confirmed by observation of cell membrane blebbing and formation of apoptotic bodies under a fluorescence microscope. The number of apoptotic nuclei was counted by a hemocytometer. At least 500 cells were examined for the calculation of apoptotic percentage in each treatment.

**Cell number assay.** To evaluate the effect of celecoxib on cell proliferation, the cells were plated at a density of 1 × 10⁶ cells per 60-mm Petri dish in complete medium for 12 h. Then the cells were treated with 0–80 μM celecoxib for 24 h. At the end of treatment, the cells were washed twice with PBS and re-cultured in complete medium for 1–7 days. The total cell number was counted by a hemocytometer.

**Immunofluorescence staining and confocal microscopy.** To view the localization and expression of proteins after celecoxib treatment, the cells were subjected to immunofluorescence staining and confocal microscopy as described (Chao and Liu, 2006). After fixation with 4% paraformaldehyde solution, the cells were washed three times with PBS, and non-specific binding sites were blocked in PBS containing 10% FBS and 0.3% Triton X-100 for 1 h. Thereafter, the cells were incubated with rabbit anti-survivin (1:50), rabbit anti-phospho-p38 (1:100), or mouse anti-γ-H2AX (1:100) antibodies in PBS containing 10% FBS overnight at 4 °C, and washed three times with 0.3% Triton X-100 in PBS. Then the cells were incubated with goat-rabbit anti-γ-H2AX (1:100), goat anti-mouse FITC-labeled IgG (1:50) in PBS containing 10% FBS overnight at 4 °C, and washed three times with 0.3% Triton X-100 in PBS. The mouse-anti-tubulin, F-actin, and nuclei were stained with the Cy3-labeled anti-γ-tubulin, BODIPY FL phallacidin, Hoechst 33258, respectively. The samples were immediately examined under a Leica confocal laser scanning microscope (Leica, Wetzlar, Germany).

**Western blot.** Briefly, proteins were separated on 10–12% sodium dodecyl sulfate–polyacrylamide gels, and transferred electrophoretically onto polyvinylidene difluoride membranes. The membranes were sequentially hybridized with primary antibody and followed with a horseradish peroxidase-conjugated secondary antibody. Thereafter, the protein bands were visualized on the X-ray film using the enhanced chemiluminescence detection system (PerkinElmer Life and Analytical Sciences, Boston, MA). A gel-digitizing software, Un-Scan-It gel (ver. 5.1; Silk Scientific, Inc., Orem, UT), was used to quantify the relative intensity.

**Construction of a green fluorescence protein (GFP)– survivin fusion vector.** The full-length human survivin cDNA was amplified by polymerase chain reaction by a pair of primer (forward: 5'-GGGCATTATGGTGTCCTGGCGA3' and reverse: 5'-GATCCATGGACGCGAGGCT3'). The survivin cDNA fragment was cloned into a CT–GFP TOPO vector by using a CT–GFP fusion TOPO expression kit (K4820-101, Invitrogen) according to the manufacturer’s recommendations. The Escherichia coli strain (BL21 DE3) was transformed with the control or survivin expression vectors for vector amplification. The successful clones of survivin-expressed vectors in E. coli were confirmed by survivin DNA sequencing. One of the successful survivin-expressed vectors was named pCT–GFP–sur8 and the control vector pCT–GFP2.

**Transfection.** Control siRNA, survivin siRNA, pCT–GFP2 and pCT–GFP–sur8 were employed for transfection using Lipofectamine™ 2000 (Invitrogen).
according to the manufacturer’s recommendations. After transfection, the cells were subjected to cytotoxicity, cell number, or Western blot analysis as described above.

**Statistical analysis.** Data were analyzed by one-way or two-way analysis of variance (ANOVA), and further post-hoc tests using the statistic software of GraphPad Prism 4 (GraphPad software, Inc. San Diego, CA). Differences between control and celecoxib-treated samples were compared by one-way ANOVA with post-hoc Tukey’s tests. Differences among control, siRNA, vector, or inhibitor after celecoxib treatments were compared by two-way ANOVA with Bonferroni post-tests. A p value of <0.05 was considered statistically significant.

**Results**

**Celecoxib induces both apoptosis and growth arrest in colorectal carcinoma cells**

The effects of celecoxib on the cell cycle progression in human RKO colorectal cancer cells were examined by flow cytometer (Fig. 1A). The G1 phase of RKO cells was elevated by 40–60 μM but was reduced by 100 μM celecoxib; however, the fraction of S phase was reduced by celecoxib in RKO cells (Fig. 1C). Celecoxib did not significantly alter the G2/M fractions (Fig. 1D). Meanwhile, celecoxib concentration-dependently increased the fraction of sub-G1 indicating apoptotic induction (Fig. 1E). The percentage of apoptotic cells was counted by nuclear staining under a fluorescence microscope. Treatment with 60 μM celecoxib for 24 h increased apoptosis by about 10% in RKO cells (data not shown). Furthermore, the total cell number was inhibited by celecoxib via a concentration-dependent manner in RKO cells (Fig. 2).

**Celecoxib inhibits the survivin protein expression and elevates the caspase-3 activation**

As shown in Fig. 3A, treatment with 40–100 μM celecoxib for 24 h significantly reduced the survivin protein expression in RKO cells. In contrast, the active forms of caspase-3 (17 kDa) were induced by celecoxib treatment (Fig. 3A). ERK-2 protein was used as an internal control in this study, which was not altered by celecoxib. The red fluorescence intensity exhibited by survivin in RKO cells was significantly decreased when exposed to celecoxib (Fig. 3B). The arrow indicated an apoptotic cell with the disappearance of survivin proteins (Fig. 3B, arrow). Moreover, the cytoskeleton of F-actin was disrupted in the celecoxib-induced apoptotic cell.

**Induction of γ-H2AX is accompanied by the phosphorylation of p38 MAP kinase in the celecoxib-exposed cells**

We have investigated the phosphorylation of p38 MAP kinase and γ-H2AX after treatment with celecoxib in human colorectal carcinoma cells. Treatment with celecoxib (40–100 μM for 24 h) increased the phosphorylated proteins of p38 MAP kinase in RKO cells (Fig. 4). The level of γ-H2AX proteins was

---

**Fig. 1. The effect of celecoxib on the cell cycle progression and apoptosis. (A) RKO cells were treated with 0–100 μM celecoxib for 24 h. At the end of treatment, the cells were trypsinized and then subjected to flow cytometry analyses. (B–E) The populations of G1, S, G2/M, and sub-G1 cells were quantified. Results were obtained from 3 to 4 experiments and the bar represents the mean ± S.E. p<0.05 (*) and p<0.01 (**), indicate between control and celecoxib treated samples.**
Increased subsequent to the activation of p38 MAP kinase in the celecoxib-treated cells (Fig. 4).

**Inhibition of p38 MAP kinase rescues the survivin protein expression and reduces cytotoxicity, γ-H2AX, and active caspase-3 in the celecoxib-exposed cells**

To examine the protein expression and location of phospho-p38 and γ-H2AX following celecoxib treatment, the colorectal carcinoma cells were subjected to immunofluorescence staining and confocal microscopy. The red fluorescence (Cy5) intensity exhibited by phospho-p38 proteins was increased and presented on the apoptotic cells by exposure to 60 μM celecoxib for 24 h in RKO cells (Fig. 5A). The γ-H2AX proteins were highly elevated and located on the apoptotic nuclei (Fig. 5B, arrows).

We have further analyzed a well-known substrate of p38 MAP kinase, ATF-2, after treatment with celecoxib in colon cancer cells. The total protein level of ATF-2 was not altered by celecoxib (Fig. 6A). However, celecoxib increased the phospho-ATF-2 proteins in RKO cells by approximately 3-fold (Fig. 6A). The level of phospho-ATF-2 was reduced after pretreatment with the specific p38 MAP kinase inhibitor, SB203580, in the celecoxib-exposed cells (Fig. 6A). Treatment with SB203580 reversed the survivin protein expression and simultaneously reduced the protein levels of γ-H2AX and active caspase-3 in the celecoxib-treated cells (Fig. 6B). The p values of phospho-ATF-2, γ-H2AX, survivin, and active caspase-3 were <0.05, which indicated significant differences between celecoxib alone and pre-treatment with SB203580 (Fig. 6B). SB203580 alone did not obviously alter the protein levels of survivin, γ-H2AX, and active caspase-3 in RKO cells (Fig. 6B). Furthermore, SB203580 significantly reduced the celecoxib-induced cell death in RKO cells (Fig. 6C).

**Survivin gene knockdown increases the level of γ-H2AX and additively elevates the celecoxib-induced cytotoxicity**

To examine the blockade of survivin expression on the regulation of celecoxib-induced apoptosis, the cells were transfected with a survivin siRNA. As shown in Fig. 7A, the levels of survivin proteins were diminished when RKO cells were transfected with 50 nM survivin siRNA. Concomitantly, the γ-H2AX proteins were elevated by transfection with survivin siRNA in RKO cells.
RKO cells (Fig. 7A). The p values of survivin and γ-H2AX were <0.05, which indicated significant difference between transfection with control and survivin siRNA (Fig. 7A). As shown in Fig. 7B, celecoxib (60 μM for 24 h) significantly reduced the cell viability in RKO cells. Transfection of survivin siRNA (50 nM for 48 h) increased cell death by about 20% when compared to control siRNA in RKO cells (Fig. 7B). Furthermore, transfection with survivin siRNA additively elevated the celecoxib-induced cytotoxicity (Fig. 7B).

Overexpression of survivin increases the cell proliferation and resists the celecoxib-induced cell death in colorectal carcinoma cells

To further determine the role of survivin in regulating the cell proliferation and the celecoxib-induced apoptosis, we have constructed a survivin-expressed vector (pCT–GFP–sur8). Immunoblot analysis showed that transfection with pCT–GFP–sur8 vector expressed a survivin–GFP–fusion protein (43.5 kDa) by using anti-GFP or anti-survivin antibodies in RKO cells (Fig. 8A). The endogenous survivin proteins in RKO cells were recognized as the 16.5 kDa proteins (Fig. 8A). The control pCT–GFP2 vector expressed the GFP proteins (27 kDa) in these cells (Fig. 8A). Unexpectedly, anti-GFP antibody recognized a non-specific protein band (Fig. 8A). Green fluorescence indicated the expression of survivin–GFP–fusion proteins after transfection with pCT–GFP–sur8 vector (Fig. 8B). The arrows indicated the overexpressed survivin proteins in RKO cells (Fig. 8B). Moreover, the total cell number was augmented after transfection with pCT–GFP–sur8 vector (Fig. 8C). Overexpression of survivin by pCT–GFP–sur8 vector also increased the cell viability in RKO cells (Fig. 8D). Besides, the transfection of pCT–GFP–sur8 vector was more resistant to the celecoxib-induced cell death than control vector (Fig. 8D).

Discussion

In this study, we provide several lines of evidence on the role of survivin in regulating the celecoxib-induced apoptosis in colorectal carcinoma cells. The gene knockdown of survivin expression increased the celecoxib-induced cell death. Conversely, overexpression of survivin elevated cancer cell proliferation and resisted the celecoxib-induced apoptosis. These findings illustrate that the suppression of survivin by celecoxib mediates...
the apoptosis and growth arrest in human colorectal cancers. Therefore, the blockade of survivin by celecoxib provides an important strategy for cancer therapy.

The phosphorylation of p38 MAP kinase was elicited by celecoxib in colorectal cancer cells. The p38 MAP kinase has been associated with the induction of apoptosis in response to many different cellular stresses (Schwenger et al., 1997; Takekawa et al., 2000; Kim et al., 2002). Celecoxib increased caspase-3 activation and apoptosis. Indeed, celecoxib has been shown to induce the activation of caspase-3 and caspase-9 (Dandekar et al., 2005; Ding et al., 2005). Our results showed that the specific p38 MAP kinase inhibitor, SB203580, attenuated active caspase-3 and cytotoxicity in the celecoxib-exposed cells; concomitantly, the survivin protein expression was restored. Accordingly, these data indicate that p38 MAP kinase may mediate apoptosis by the down-regulation of survivin.

This is the first report that celecoxib induces the phosphorylation of H2AX, and the gene knockdown of survivin also elevated the γ-H2AX induction. H2AX is a variant of H2A of...
histones that functions to maintain genomic stability (Paull et al., 2000; Redon et al., 2002). Phosphorylation of H2AX at serine-193, named γ-H2AX, is induced by DNA damage agents such as irradiation (Paull et al., 2000; Redon et al., 2002). Besides, the γ-H2AX formation is due to caspase-controlled DNA fragmentation in the course of apoptosis which facilitates the packaging of fragmented DNA into apoptotic bodies (Rogakou et al., 2000). We found that the phosphorylated proteins of p38 MAP kinase and γ-H2AX were located on the apoptotic bodies. Moreover, the inhibition of p38 MAP kinase by SB203580 reduced the level of γ-H2AX in the celecoxib-exposed cells. These results suggest that the down-regulation of survivin by p38 MAP kinase can induce the activation of γ-H2AX and caspase-3 for apoptotic induction.

It has been shown that survivin protein can be stabilized by the COX-2 overexpression leading to the reduction of apoptosis in cancer cells (Krysan et al., 2004). However, Pyrko et al. (2006) recently reported that the suppression of survivin by celecoxib was via a COX-independent pathway. In addition, celecoxib has been shown to mediate cell cycle arrest and
apoptosis via COX-2-independent pathways in human cholangiocarcinoma and prostate cancer cells (Han et al., 2004; Kulp et al., 2004). Indeed, the gene knockout of COX-2 did not significantly induce the phosphorylation of p38 MAP kinase in colorectal cancer cells (unpublished data). Therefore, we suggest that the activation of p38 MAP kinase by celecoxib results from a COX-2-independent pathway. Nevertheless, the precise mechanisms of COX-2-dependent and -independent pathways on apoptosis after treatment with celecoxib need further investigation.

In conclusion, we propose that survivin plays an important role in the celecoxib-mediated apoptosis, and p38 MAP kinase may down-regulate the survivin expression. Understanding the mechanisms by which these signal molecules mediate the celecoxib-induced growth arrest and apoptosis in human cancer cells may provide a novel strategy in cancer therapy.

References


